Clinipace, a US company founded in 2004 that supplies clinical research software to academic medical centres as well as contract research organisations and biopharmaceutical or medical device companies, has been awarded 10 new projects worth more than US$10 million in aggregate.

The projects include early-stage clinical trials, registries and investigator-initiated research grant management for mid-tier life sciences companies, research networks and foundations.

They will help to maintain the rapid growth trajectory of a company that has boosted its staffing – currently some 24 employees – by more than 50% since it closed a US$2.6 million Series B financing led by Hatteras Venture Partners in January. Most of the staff additions were in Clinipace’s sales and services teams.

In recent months the company, based in Morrisville, North Carolina, has signed up five new customers, including Inspire Pharmaceuticals, VaxInnate, SHS International and the Crohn’s and Colitis Foundation of America, as well as securing five additional software projects from existing customers.

“We are committed to serving the needs of emerging and mid-tier biopharmaceutical and medical device firms, as well as academic researchers, research networks and foundations,” commented Jeff Williams, chief executive officer of Clinipace, adding that these organisations have been “largely ignored by established eClinical software vendors because of their size and budget constraints”.

Clinipace can deliver its solutions at a cost 30-50% below that of comparable systems, Williams said. “In this way, we are democratising eClinical software, ensuring that every organisation has access to an easy-to-use and comprehensive system that spans the clinical trial life cycle and empowers all constituents.”

The company’s TEMPO technology provides a single, integrated data capture and study management platform for clinical trials, investigator-initiated research grant management and registries, delivered via a web-based, on-demand architecture.